Premium
Adjuvant chemotherapy of gastric carcinoma: A pilot study of oral administration of injectable 5‐fluorouracil
Author(s) -
Wu YongFang
Publication year - 1985
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930280317
Subject(s) - medicine , fluorouracil , oral administration , gastric carcinoma , chemotherapy , tegafur , cancer , adenocarcinoma , adjuvant , gastroenterology , adjuvant chemotherapy , gastric adenocarcinoma , clinical trial , surgery , oncology , breast cancer
During the past three years we have entered 54 patients with gastric adenocarcinoma into a clinical trial of oral administration of injectable 5‐fluorouracil (5‐Fu). Of the 20 unresectable advanced cases, the median survival was 6.2 months, and for 34 resectable ones, median survival was 22 months. These results were comparable to those reported in the literature. It is also safe, easy to administer, well tolerated, and does not have any apparent side effects. The author discovered for the first time that oral administration of 5‐Fu could improve the liver function as manifested by a marked decrease of serum GPT level in advanced gastric cancer.